Latest filing published 31 Aug 2026 for Jazz Pharmaceuticals plc, €2.5M. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Robert Iannone is a declared insider of Jazz Pharmaceuticals plc (senior executive), with filings sourced from SEC (Form 4). We count 27 filings; the first trade dates from 5 June 2021 and the latest from 27 August 2026.
Every open-market trade on record is a sale: 9 sales worth €18.1M. Other entries cover 12 share grants and 4 option exercises. So far in 2026, the count stands at no purchases and 6 sales.
On 31 August 2026 came the latest disclosure, an open-market sale for €3.9M in Jazz Pharmaceuticals plc. The median gap between a trade and its publication by SEC (Form 4) is 4 days. US insiders must file a Form 4 within two business days of a trade. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
25 of 27 declarations